Spark Therapeutics’ Luxturna nears FDA approval for gene therapy treating inherited blindness
Luxturna FDA approval news : An FDA panel has recommended the approval of Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics for treating a rare form of genetically inherited form of blindness.
In a significant development in gene therapy, Spark Therapeutics’ Luxturna (voretigene neparvovec) is on the verge of receiving FDA approval for treating blindness caused by inherited retinal diseases (IRD), specifically those mediated by the RPE65 gene mutation. This breakthrough follows a unanimous recommendation from the 16-member Cellular, Tissue, and Gene Therapies Advisory Committee of the […]